Joleen M. Hubbard1; Matti Aapro2; Satish Shah3; Afshin Eli Gabayan4; Richard Siegel5; Yili Pritchett6; John Yi6; Janet Horton6; and Fortunato Ciardiello7
For questions regarding the PRESERVE 1 trial, please contact email@example.com. Copies of this e-Poster obtained through QR, AR, and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.
1Mayo Clinic, Rochester, MN, USA; 2Genolier Cancer Center, Clinique de Genolier, Genolier, Switzerland; 3Gettysburg Cancer Center, Gettysburg, PA, USA; 4Beverly Hills Cancer Center, Beverly Hills, CA, USA; 5Illinois Cancer Specialists, Arlington Heights, IL, USA; 6G1 Therapeutics, Inc., Research Triangle Park, NC, USA; 7University of Campania Luigi Vanvitelli, Naples, Italy
ESMO Congress 2021 | September 16–21, 2021 | Virtual
PRESERVE 1 STUDY
Study sponsored by G1 Therapeutics. Medical writing assistance was provided by Farhana Burnett, PhD, from Alligent Europe (Envision Pharma Group), funded by G1 Therapeutics, Inc.